Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc.

Date Founded



800 Saginaw Drive, Redwood CIty, CA, 94063, USA

Type of Company


Employees (Worldwide)




Company Description

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer, and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Redwood City, CA.

Contact Data
Trying to get in touch with decision makers at Adverum Biotechnologies, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer, President & Director

Executive Director, Process Development & Manufacturing

Chief Financial & Accounting Officer

Chief Operating Officer

Vice President, Quality

Vice President, Investor Relations & Corporate Communications

Vice President, Human Resources

Vice President, Commercial & Program Strategy

Chief Scientific Officer

Vice President-Clinical Affairs

Board of Directors

Co-Founder at Medivation LLC (California)

President at American Telemedicine Association

Venture Partner at Versant Venture Management LLC

Chief Executive Officer, President & Director at Adverum Biotechnologies, Inc.

Managing Director at MPM Asset Management LLC

Former President-Europe & Canada Region at Merck & Co., Inc.

Venture Partner at Vivo Capital LLC

Scientific Co-Founder at GENSIGHT BIOLOGICS S.A.

Former Senior Director-Product Development at Ceregene, Inc.

Former Vice President-Translational Pharmacology at Sutro Biopharma, Inc.

Paths to Adverum Biotechnologies, Inc.
Potential Connections via
Relationship Science
Adverum Biotechnologies, Inc.
Owners & Shareholders
Details Hidden

Versant Ventures is an active manager which invests in biotechnology companies located globally. The firm participates in early and later stage capital requirements.

Details Hidden

K2 & Associates Investment Management uses multiple leveraging and hedging techniques to exploit the information and liquidity disparity surrounding less-followed transactions. The firm employs an active trading style and fundamental industry and company-specific research. They tend to invest in the stocks of small-cap US, Canadian and European companies in the energy minerals, non-energy minerals and finance sectors.

Recent Transactions
Details Hidden

Adverum Biotechnologies, Inc. issued USD Common Stock

Details Hidden

Adverum Biotechnologies, Inc. issued USD Common Stock

Details Hidden

Adverum Biotechnologies, Inc. issued . USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Transaction Advisors

Advised onAdverum Biotechnologies, Inc. issued USD Common Stock

Legal Advisor

Advised onAdverum Biotechnologies, Inc. issued USD Common Stock


Advised onAdverum Biotechnologies, Inc. issued USD Common Stock


Advised onAdverum Biotechnologies, Inc. issued USD Common Stock

Legal Advisor

Advised onAdverum Biotechnologies, Inc. issued USD Common Stock


Advised onAdverum Biotechnologies, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner at Gibson, Dunn & Crutcher LLP

Legal Advisor

Partner, New York at Cooley LLP

Legal Advisor

Partner at Wilson Sonsini Goodrich & Rosati PC


GenSight Biologics SA is a clinical-stage gene therapy company. It engages in research and development of novel therapies for mitochondrial and neurodegenerative. The company also provides ophthalmology services which develops products to restore eyesight to patients suffering from retinal diseases. GenSight Biologics was founded by Bernard Jacques Alex Gilly, Botond Roska, Jean Bennett, Connie Cepko, Luk H. Vandenberghe, Serge Picaud and Jose-Alain Sahel in 2012 and is headquartered in Paris, France.

Key Stats and Financials As of 2020
Market Capitalization
Total Enterprise Value
Earnings Per Share
Net Profit
Total Debt
Total Equity
TEVNet Income
Debt TEV
Three Year Compounded Annual Growth Rate Of Revenue
Details Hidden

Silver Point Capital specializes in taking long and short positions distressed debt and credit-focused securities. The firm's investment strategy with respect to the Flagship Funds focuses on making investments in debt, equity or other securities, obligations or instruments of misvalued, mislevered, leveraged or financially distressed companies and in event-oriented and other special situations. The Flagship Funds may hold both long and short positions in such investments.

Details Hidden

SilverArc Capital Management LLC is an American private company located in Boston, MA, that provides investment advice. The firm was founded in 2019 by Devesh Sharad Gandhi, who has been the CEO since then.

Details Hidden

Senator pursues a global and opportunistic strategy for investing in distressed debt, value equities and event equities. They also pursue a global and opportunistic strategy for investing in “less-than-liquid” situations, including private or illiquid debt and equity investments. The firm emphasizes capital preservation and seeks to mitigate risk. Their allocation of capital depends upon where it believes the most attractive risk-adjusted opportunities exist.

University of California Other Business & Consulting Services | Oakland, CA

The University is governed by The Regents, which under Article IX, Section 9 of the California Constitution has "full powers of organization and governance" subject only to very specific areas of legislative control. The article states that "the university shall be entirely independent of all political and sectarian influence and kept free therefrom in the appointment of its Regents and in the administration of its affairs." Board Membership Article IX, Section 9 was drafted in 1878 after a decade of political conflict demonstrated the importance of sheltering the university from shifting political winds. The board consists of 26 members: 18 regents are appointed by the governor for 12-year terms One is a student appointed by the Regents to a one-year term Seven are ex officio members -- the Governor, Lieutenant Governor, Speaker of the Assembly, Superintendent of Public Instruction, president and vice president of the Alumni Associations of UC and the UC president. In addition, two faculty members -- the chair and vice chair of the Academic Council -- sit on the board as non-voting members. Board Officers The Governor is officially the president of the Board of Regents; however, in practice the presiding officer of the Regents is the Chairman of the Board, elected from among its body for a one-year term, beginning July 1. The current Chairman is Regent Sherry Lansing. The Vice Chairman is Regent Bruce Varner. The Regents appoints Officers of The Regents: the General Counsel; the Chief Investment Officer; the Secretary and Chief of Staff; and the Chief Compliance and Audit Officer. Former Regents Here is a list of individuals who have served as Regents of the University of California: Former Regents Committees and Meetings The Regents operates through 10 standing committees: Compliance and Audit, Compensation, Educational Policy, Finance, Governance, Grounds and Buildings, Health Services, Investments, Long Range Planning, and Oversight of the Department of Energy Laboratories. The Regents meets six times a year every other month in two-day meetings

Virovek, Inc. Industrial Machinery & Manufacturing | Hayward, CA

Virovek, Inc. is an American private company located in Hayward, CA, that operates as an adeno-associated virus production and protein expression services company.

Cornell University Computer Software | Ithaca, New York

Cornell is a privately endowed research university and a partner of the State University of New York. As the federal land-grant institution in New York State, they have a responsibility—unique within the Ivy League—to make contributions in all fields of knowledge in a manner that prioritizes public engagement to help improve the quality of life in our state, the nation, the world.

Regeneron Pharmaceuticals, Inc. Pharmaceuticals - Tarrytown, New York

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government. Johnson & Johnson is headquartered in New Brunswick, New Jersey, the consumer division being located in Skillman, New Jersey. The corporation includes some 250 subsidiary companies with operations in 60 countries and products sold in over 175 countries. Johnson & Johnson had worldwide sales of $82.6 billion during calendar year 2020. Johnson & Johnson's brands include numerous household names of medications and first aid supplies. Among its well-known consumer products are the Band-Aid Brand line of bandages, Tylenol medications, Johnson's Baby products, Neutrogena skin and beauty products, Clean & Clear facial wash and Acuvue contact lenses. Johnson & Johnson's pharmaceutical arm is Janssen Pharmaceutica.

Roche Holding AG Pharmaceuticals - Basel, Switzerland

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Adverum Biotechnologies, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Adverum Biotechnologies, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Adverum Biotechnologies, Inc..